Kaneka Corporation Stock

Equities

4118

JP3215800008

Commodity Chemicals

Market Closed - Japan Exchange 02:00:00 2024-04-23 am EDT 5-day change 1st Jan Change
4,006 JPY +0.93% Intraday chart for Kaneka Corporation +1.06% +11.84%
Sales 2024 * 768B 4.96B Sales 2025 * 801B 5.17B Capitalization 256B 1.66B
Net income 2024 * 22.72B 147M Net income 2025 * 24.73B 160M EV / Sales 2024 * 0.5 x
Net Debt 2024 * 127B 823M Net Debt 2025 * 133B 861M EV / Sales 2025 * 0.49 x
P/E ratio 2024 *
11.3 x
P/E ratio 2025 *
10.3 x
Employees 11,545
Yield 2024 *
2.77%
Yield 2025 *
2.94%
Free-Float 87.41%
More Fundamentals * Assessed data
Dynamic Chart
Tranche Update on Kaneka Corporation's Equity Buyback Plan announced on February 8, 2024. CI
Kaneka Corporation announces an Equity Buyback for 2,000,000 shares, representing 3.08% for ¥8,000 million. CI
Kaneka Corporation authorizes a Buyback Plan. CI
Kaneka Corporation acquired Japan Medical Device Technology Co., Ltd. CI
Sun-Novo Pharma Gets License to Produce Kaneka’s Transdermal Patches MT
Kaneka Corporation Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Tranche Update on Kaneka Corporation's Equity Buyback Plan announced on September 9, 2022. CI
Kaneka Corporation's Equity Buyback announced on September 9, 2022 has closed with 2,300,000 shares, representing 3.47% for ¥8,042.21 million. CI
Tranche Update on Kaneka Corporation's Equity Buyback Plan announced on September 9, 2022. CI
Kaneka Corporation Announces Manufacture and Supply Intermediates to Shionogi & Co., Ltd for Use in Xocova® CI
Tranche Update on Kaneka Corporation's Equity Buyback Plan announced on September 9, 2022. CI
Kaneka Corporation announces an Equity Buyback for 2,300,000 shares, representing 3.42% for ¥10,000 million. CI
Kaneka Corporation authorizes a Buyback Plan. CI
Kaneka Corporation agreed to acquire remaining 45.24% stake in Cemedine Co., Ltd.. CI
Kaneka Launches New PCR Test Kit for Identifying the COVID-19 Omicron (BA.1) and "Stealth" Omicron (BA.2) Variants CI
More news
1 day+0.93%
1 week+1.06%
Current month+5.03%
1 month+4.16%
3 months+9.75%
6 months+7.66%
Current year+11.84%
More quotes
1 week
3 832.00
Extreme 3832
4 050.00
1 month
3 738.00
Extreme 3738
4 056.00
Current year
3 522.00
Extreme 3522
4 056.00
1 year
3 456.00
Extreme 3456
4 288.00
3 years
3 165.00
Extreme 3165
4 990.00
5 years
2 112.00
Extreme 2112
5 000.00
10 years
2 112.00
Extreme 2112
6 390.00
More quotes
Managers TitleAgeSince
President 62 85-03-31
Chairman 77 70-03-31
Director/Board Member 64 87-03-31
Members of the board TitleAgeSince
Chairman 77 70-03-31
Director/Board Member 64 87-03-31
Corporate Officer/Principal 67 81-03-31
More insiders
Date Price Change Volume
24-04-23 4,006 +0.93% 281 500
24-04-22 3,969 +2.03% 128,600
24-04-19 3,890 -1.27% 184,900
24-04-18 3,940 +0.46% 106,600
24-04-17 3,922 -1.06% 137,900

Delayed Quote Japan Exchange, April 23, 2024 at 02:00 am EDT

More quotes
KANEKA CORPORATION is a Japan-based company engaged in four business segments. The Material Solutions Unit segment includes general purpose vinyl chloride resin, caustic soda, polyvinyl chloride special resin, modifier, modified silicone polymer, biodegradable polymer. Quality of Life Solutions Unit segment includes expanded styrene resin and molded products, extruded polystyrene foam boards, bead method expanded polyolefin, solar circuit method, super heat resistant polyimide films, optical materials, super heat conductive graphite sheets, solar cells, storage batteries for housing and others. The Health Care Solutions Unit segment includes medical devices, low molecular weight pharmaceutical raw materials, biopharmaceuticals, etc. The Nutrition Solutions Unit segment includes functional food ingredients, margarine, shortening, baker's yeast, spices, antifreeze ingredients, functional fertilizers and feeds.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
3,969 JPY
Average target price
4,091 JPY
Spread / Average Target
+3.08%
Consensus